Genentech makes $1.5B+ deal with AI heavyweight Earendil for cancer bispecifics

PartnershipPositive

AI Analysis

Summary

Genentech entered a deal worth $1.5B+ with AI company Earendil Labs for cancer bispecific development, while parent company Roche simultaneously signed a cardiometabolic and renal disease partnership with Atavistik Bio valued up to $2 billion.

Importance:7/10

Sentiment:

0.70

partnershipacquisitioncancerbispecificsAIcardiometabolicrenal disease

Related Companies

$RHHBY

Read the original article

Published by BioSpace on September 25, 2026 12:27 PM

Read Original